The WHO Classification of Urinary and Male Genital Tumours 2022: renal tumours classification

Czech version

Authors: Adriena Bartoš Veselá ¹; Tomáš Pitra ¹; Jiří Kolář ¹; Josef Skopal ²; Ondřej Fiala ³; Milan Hora ¹; Ondřej Hes ^2,4; Kristýna Pivovarčíková ^2,4; Zesnulý
Authors‘ workplace: Urologická klinika, Lékařská fakulta Plzeň, Univerzita Karlova a Fakultní nemocnice Plzeň ¹; Šiklův ústav patologie, Lékařská fakulta Plzeň, Univerzita Karlova a Fakultní nemocnice Plzeň ²; Onkologická a radioterapeutická klinika, Lékařská fakulta Plzeň, Univerzita Karlova a Fakultní, nemocnice Plzeň a Biomedicínské centrum, Lékařská fakulta Plzeň, Univerzita Karlova ³; Bioptická laboratoř, s. r. o., Plzeň ⁴
Published in: Ces Urol 2023; 27(2): 70-77
Category: Review articles

Overview

The 5th edition WHO (World Health Organization) classification of the urogenital tract tumors was published in the middle of last year (so-called blue book). The new WHO classification reflects very dynamic developments in the field of renal neoplasms (caused mainly by the more frequent implementation of molecular genetic testing into the routine diagnosis of kidney tumors), and the new WHO classification shows changes especially in the chapter on renal tumors. The new kidney tumor classification modifies some traditional entities and also redefines and includes some new kidney tumors. This review article aims to briefly outline and comment on the most significant changes in the WHO classification of renal neoplasia.

Keywords:

urogenital tract – Molecular pathology – Renal cell carcinoma – renal tumours – WHO 2022 classification.

Sources

1. Amin MB, Gill Aj, Hartmann A, et al. Chapter 2: tumours of the kidney. In: WHO Classification of Tumours Editorial Board. Urinary and male genital tumours. 5. ed. Lyon: IARC 2022: 32–130.

2. Eble JN, Sauter G, Epstein JI, Sesterhenn I. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs.

3. ed. Lyon: IARC Press; 2004. 3. Moch H, Humphrey P, Ulbright TM, Reuter VE. WHO Classification of tumours of the urinary system and male genital organs. 4. ed. Lyon: IARC 2016.

4. Williamson SR, Gill AJ, Argani P, et al. Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers: III: Molecular Pathology of Kidney Cancer. Am J Surg Pathol. 2020; 44(7): e47–65.

5. Trpkov K, Williamson SR, Gill AJ, et al. Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Mod Pathol. 2021; 34(6): 1167–1184.

6. Trpkov K, Hes O, Williamson SR, et al. New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Mod Pathol. 2021; 34(7): 1392–1424.

7. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol. 1997; 10(6): 537–544.

8. Pitra T, Pivovarcikova K, Alaghehbandan R, Hes O. Chromosomal numerical aberration pattern in papillary renal cell carcinoma: Review article. Ann Diagn Pathol. 2019; 40: 189–199.

9. Pivovarcikova K, Peckova K, Martinek P, et al. „Mucin“-secreting papillary renal cell carcinoma: clinicopathological, immunohistochemical, and molecular genetic analysis of seven cases. Virchows Arch. 2016; 469(1): 71–80.

10. Rogala J, Kojima F, Alaghehbandan R, et al. Papillary renal cell carcinoma with prominent spindle cell stroma – tumor mimicking mixed epithelial and stromal tumor of the kidney: Clinicopathologic, morphologic, immunohistochemical and molecular genetic analysis of 6 cases. Ann Diagn Pathol. 2020; 44: 151441.

11. Ulamec M, Skenderi F, Trpkov K, et al. Solid papillary renal cell carcinoma: clinicopathologic, morphologic, and immunohistochemical analysis of 10 cases and review of the literature. Ann Diagn Pathol. 2016; 23: 51–57.

12. Skenderi F, Ulamec M, Vanecek T, et al. Warthin‑like papillary renal cell carcinoma: Clinicopathologic, morphologic, immunohistochemical and molecular genetic analysis of 11 cases. Ann Diagn Pathol. 2017; 27: 48–56.

13. Hes O, Condom Mundo E, Peckova K, et al. Biphasic Squamoid Alveolar Renal Cell Carcinoma: A Distinctive Subtype of Papillary Renal Cell Carcinoma? Am J Surg Pathol. 2016; 40(5): 664–675.

14. Pivovarcikova K, Grossmann P, Hajkova V, et al. Renal cell carcinomas with tubulopapillary architecture and oncocytic cells: Molecular analysis of 39 difficult tumors to classify. Ann Diagn Pathol. 2021; 52: 151734.

15. Williamson SR, Hes O, Trpkov K, et al. Low‑grade oncocytic tumour of the kidney is characterised by genetic alterations of TSC1, TSC2, MTOR or PIK3CA and consistent GATA3 positivity. Histopathology. 2023; 82(2): 296–304.

16. He H, Trpkov K, Martinek P, et al. „High‑grade oncocytic renal tumor“: morphologic, immunohistochemical, and molecular genetic study of 14 cases. Virchows Arch. 2018; 473(6): 725–738.

17. Farcaş M, Gatalica Z, Trpkov K, et al. Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC/MTOR mutations: next‑generation sequencing multi‑institutional study of 19 cases. Mod Pathol. 2022; 35(3): 344–351.

18. Pivovarcikova K, Alaghehbandan R, Vanecek T, et al. TSC/mTOR Pathway Mutation Associated Eosinophilic/ Oncocytic Renal Neoplasms: A Heterogeneous Group of Tumors with Distinct Morphology, Immunohistochemical Profile, and Similar Genetic Background. Biomedicines. 2022; 10(2): 322.

19. Hora M, Albiges L, Bedke J, et al. European Association of Urology Guidelines Panel on Renal Cell Carcinoma Update on the New World Health Organization Classification of Kidney Tumours 2022: The Urologist’s Point of View. Eur Urol. 2023; 83(2): 97–100.

20. Williamson SR. Clear cell papillary renal cell carcinoma: an update after 15 years. Pathology 2021; 53(1): 109–119.

21. Trpkov K, Hes O, Bonert M, et al. Eosinophilic, Solid, and Cystic Renal Cell Carcinoma: Clinicopathologic Study of 16 Unique, Sporadic Neoplasms Occurring in Women. Am J Surg Pathol. 2016; 40(1): 60–71.

22. Mehra R, Vats P, Cao X, et al. Somatic Bi‑allelic Loss of TSC Genes in Eosinophilic Solid and Cystic Renal Cell Carcinoma. Eur Urol. 2018; 74(4): 483–486.

23. McKenney JK, Przybycin CG, Trpkov K, Magi‑Galluzzi C. Eosinophilic solid and cystic renal cell carcinomas have metastatic potential. Histopathology. 2018; 72(6): 1066–1067.

24. Argani P, Reuter VE, Zhang L, et al. TFEB‑amplified Renal Cell Carcinomas: An Aggressive Molecular Subset Demonstrating Variable Melanocytic Marker Expression and Morphologic Heterogeneity. Am J Surg Pathol. 2016; 40(11): 1484–1495.

25. Peckova K, Vanecek T, Martinek P, et al. Aggressive and nonaggressive translocation t(6;11) renal cell carcinoma: comparative study of 6 cases and review of the literature. Ann Diagn Pathol. 2014; 18(6): 351–357.

26. El‑Zaatari Z, Divatia MK. Hereditary leiomyomatosis and renal cell carcinoma syndrome‑associated renal cell carcinoma: Morphological appraisal with a comprehensive review of differential diagnoses. Indian J Pathol Microbiol. 2020; 63(Supplement): S7–17.

27. Kuroda N, Tsutsui M, Iguchi M, et al. Fumarate hydratase‑deficient renal cell carcinoma: A clinicopathological study of seven cases including hereditary and sporadic forms. Ann Diagn Pathol. 2020; 49: 151599.

28. Hakimi AA, Tickoo SK, Jacobsen A, et al. TCEB1-mutated renal cell carcinoma: a distinct genomic and morphological subtype. Mod Pathol. 2015; 28(6): 845–853.

29. Wang Y, Zhao P, Wang L, et al. Analysis of clinicopathological and molecular features of ELOC(TCEB1)‑ -mutant renal cell carcinoma. Pathol Res Pract. 2022; 235: 153960.

30. Shah RB, Stohr BA, Tu ZJ, et al. „Renal Cell Carcinoma With Leiomyomatous Stroma“ Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity. Am J Surg Pathol. 2020; 44(5): 571–581.

31. Iannantuono GM, Riondino S, Sganga S, Roselli M, Torino F. Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review. Int J Mol Sci. 2022; 23(7): 3995.

32. Pal SK, Bergerot P, Dizman N, et al. Responses to Alectinib in ALK‑rearranged Papillary Renal Cell Carcinoma. Eur Urol. 2018; 74(1): 124–128.

33. Calderaro J, Moroch J, Pierron G, et al. SMARCB1/INI1 inactivation in renal medullary carcinoma. Histopathology. 2012; 61(3): 428–435.